Navigation Links
Welsh shingles drug set for final hurdle
Date:3/23/2010

A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.

A new shingles drug (FV-100), discovered by Professor Chris McGuigan's team from Cardiff University's Welsh School of Pharmacy together with a virology group at the Rega Institute in Belgium and US biopharmaceutical company, Inhibitex Inc, is due to complete Phase II of its clinical trials.

If the drug completes Phase II it will enter the third and final stage which could see the drug being available to patients in less than three years.

Cardiff University's Professor of Medical Chemistry, Chris McGuigan, who led the team which discovered the new antiviral drug, said: "We are now entering the final and most crucial stage in the journey from the discovery of a new drug to the market.

"If we successfully complete this stage the drug would be available to help alleviate the pain and suffering for millions of shingles patients, not only in Wales but across the world."

Shingles is caused by the same viral infection that causes chicken pox. It is estimated that one-in-five people in the US, Europe and Japan will be affected by the condition during their lifetime.

The condition is characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic neuralgia which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Initial tests of FV-100 showed it has the potential to greatly reduce all of these symptoms.

In Phase I trials of FV-100, no serious adverse events in healthy volunteers were reported and data supported the potential for once-a-day dosing in future trials.Previous lab research has also shown the drug to be up to 10,000 times more potent against the virus than existing treatments.

Professor McGuigan added: "We believe this drug has the potential to be the most powerful inhibitor ever discovered to treat shingles.

"Each year only 15-20 new medicines are approved for clinical use and the chance of FV100 becoming an approved medicine improves the further we successfully progress through each of the clinical stages.

"We are incredibly excited at the prospect of FV-100 becoming commercially available in the future, and potentially being the first drug discovered in Cardiff University to make it to the marketplace."


'/>"/>

Contact: Chris Jones
JonesC83@cardiff.ac.uk
44-292-087-4731
Cardiff University
Source:Eurekalert

Related medicine news :

1. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
2. Chicken Pox Shot Protects Against Shingles, Too
3. Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children
4. Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco
5. AKON Fragrance Finally Available at Akonfragrances.com
6. Morehead Associates, Inc. and Child Health Corporation of America (CHCA) Finalize Agreement for Employee and Physician Surveys and Consulting Services
7. Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th
8. 21 Healthcare Companies Achieve Semi-Finalist Status for Innovations in HealthcareSM ABBY Awards
9. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Kiwanis Selects Three Finalists for Worldwide Service Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: